2015年—2019年湖州地区耐多药结核病吡嗪酰胺耐药性分析  

Resistance analysis of multidrug-resistant tuberculosis to pyrazinamide in Huzhou region from 2015 to 2019

作　　者：张思潮[1] 童涌[2] 马晓凤 徐德顺[1] ZHANG Si-chao;TONG Yong;MA Xiao-feng;XU De-shun(Huzhou Municipal Center for Disease Control and Prevention,Huzhou,Zhejiang 313000,China;不详)

机构地区：[1]湖州市疾病预防控制中心,浙江湖州313000 [2]湖州市中心医院,浙江湖州313000

出　　处：《中国卫生检验杂志》2021年第17期2080-2082,共3页Chinese Journal of Health Laboratory Technology

基　　金：耐药基因芯片技术对耐药结核早期诊疗的研究(2017-GYB30)。

摘　　要：目的了解湖州地区耐多药结核病吡嗪酰胺耐药性以及pnc A基因突变结果,为预防控制耐多药结核病的流行和临床治疗提供参考依据。方法将2015年—2019年湖州地区耐多药结核病、广泛耐药和利福平耐药患者结核分枝杆菌分离株作为对象,通过结核分枝杆菌液体培养法和pnc A基因序列分析法检测耐药情况。结果 106例耐多药结核病、广泛耐药和利福平耐药患者结核分枝杆菌分离株中,吡嗪酰胺耐药率为38.68%(41/106);41株吡嗪酰胺耐药株中,pnc A基因突变为85.37%(35/41)。结论结核分枝杆菌液体培养法和pnc A基因序列分析法一致性较高,2种方法均可为临床治疗提供参考依据。Objective To analyze the drug resistance of multidrug-resistant Mycobacterium tuberculosis strains to pyrazinamide(PZA)and the mutation of pncA gene,so as to provide reference for the prevention and control of MDR-TB and clinical medication.Methods Mycobacterium tuberculosis isolates from MDR-TB,XDR-TB and Lifampicin resistant patients in Huzhou region from 2015 to 2019 were selected as subjects.Liquid culture method and pncA gene sequence analysis were used to detect the drug resistance of Mycobacterium tuberculosis.Results Among 106 Mycobacterium tuberculosis isolates from MDR-TB,XDR-TB and Rifampicin resistant patients,the rate resistance to pyrazinamide was 38.68%(41/106).In 41 pyrazinamide resistant strains,the mutation of pncA gene was 85.37%(35/41).Conclusion There was a high consistency between the liquid culture method and the PZA gene sequence analysis method of Mycobacterium tuberculosis,which can provide reference for clinical medication.

关 键 词：耐多药结核病 吡嗪酰胺 pnc A基因 

分 类 号：R446[医药卫生—诊断学]